Compare Incyte Corporation (INCY) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street Technology Select Sector SPDR ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 5.8× Incyte Corporation's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| INCY | XLK | |
|---|---|---|
Market Cap | $22.85B | $132.55B |
Volume | 1,927,029 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $202.00 |
52-Week Low | $83.80 | $127.49 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
XLK, the Technology Select Sector SPDR ETF, trades at $198.78, down 1.3% over the past day amid broader tech sector pressure. The technical outlook remains bullish based on moving averages, with neutral oscillators suggesting consolidation near the pivot point of $199. Recent news highlights AI-driven momentum in software stocks and ETF concentration concerns, while a future dividend of $0.22 is scheduled for September 2026.
The ETF's outlook is supported by strong AI investment themes and large-cap tech earnings resilience, but risks include interest rate sensitivity and high concentration in semiconductor holdings. Analyst sentiment is mixed, with some favoring alternative tech ETFs for better diversification. Key resistance lies at $201, with support at $196.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
